pathologic myopia with CNV
Ophthalmology · 2018–2025
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aflibercept Treatment of subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) in adults. | Nov 2025 | Recommended | none received |
| ranibizumab Treatment of subfoveal choroidal neovascularisation (CNV) secondary to pathologic myopia (PM) in patients with visual impairment. | Mar 2018 | Recommended with restriction | input received |
What the PBS pays
$598M in government benefit over 2024–25, across 618,925 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aflibercept | $506.1M |
| ranibizumab | $91.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.